Key result
Transcatheter aortic valve implantation has reduced 30-day operative mortality to approximately 10% in high-risk patients, though long-term durability remains unknown.
TAVI has emerged as a promising treatment for high-risk patients with aortic valve disease, with 30-day mortality reduced to approximately 10%, though long-term durability remains unknown.
Answers are grounded in this paper and cite their sources.
May support TAVI evaluation in high-risk aortic stenosis; leaves open long-term durability for prospective trials.
There has been significant improvement in device designs, operative techniques, and early clinical outcomes in <5 years. Presently, there are two catheter-based bioprostheses (balloon expandable or self-expandable), which have been widely used in humans and are undergoing clinical investigations. Three approaches, including transvenous, transarterial, and transapical have been used for delivery of the catheter-based bioprostheses, and transarterial and transapical approaches have been adopted by cardiologists and cardiac surgeons worldwide. The most recent clinical results have been very encouraging and promising. With experience, 30-day operative mortality with either balloon-expandable or self-expandable bioprosthesis was reduced significantly to approximately 10% in high-risk patients. In vivo long-term durability of catheter-based bioprostheses remains unknown, and presently transcatheter procedure is limited to the cohort of high-risk patients. Expanding this new technology to low-risk patients should be done with extreme caution because conventional aortic valve replacement still provides the best long-term outcome with minimal operative mortality and morbidity in low-risk patients. Ongoing clinical trials will address many unanswered questions, such as patient selection, long-term in vivo durability, preoperative assessment, and the role of the procedures in management of valvular diseases.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2009) conducted a review in Aortic valve disease. Transcatheter Aortic Valve Implantation vs. Conventional aortic valve replacement was evaluated on 30-day operative mortality. Transcatheter aortic valve implantation has reduced 30-day operative mortality to approximately 10% in high-risk patients, though long-term durability remains unknown.
Synapse has enriched 10 related papers. Consider them for comparative context: